The global drug discovery services market size is projected to garner significant growth from 2023 to 2033. According to the research report published by FMI, the global market is anticipated to surpass a valuation of US$ 19.7 billion in 2023. It is likely to hit a valuation of US$ 76.5 billion by 2033. The market is projected to exhibit a captivating CAGR of 14.5% from 2023 to 2033.
New drugs are continuously required to address the various unmet medical needs. Several diseases, including neurodegenerative, cancer, rare genetics, and cardiovascular diseases still lack effective treatment. The emergence of new diseases is spiraling the demand for new drugs. Drug discovery services are expected to increase multifold due to the growing development and discovery of novel drugs.
Drug discovery requires substantial resources and time. As drug discovery becomes complex, the demand for specialized expertise across various scientific disciplines rises. Experts from toxicology, medicinal chemistry, pharmacology, and formulation development usually engage in discovering new drugs. Outsourcing these services can reduce costs and time for research institutions and pharmaceutical companies. The outsourced drug delivery services market provides access to specialized infrastructure and expertise, without any high investments.
Several pharmaceutical, biopharmaceutical, and medical device businesses devote significant resources to developing new medications and technologies. The pharmaceutical sector spends a lot of money on research and development (R&D). The research and development pharmaceutical industry brings high-quality, innovative goods to market. The top pharma companies are enhancing their R&D efficiencies through massive R&D investments to reap long-term benefits.
Initiatives for rare diseases and orphan drug research drive new income streams in the market. However, stringent rules regulating drug research and animal testing may limit market expansion to some extent. Moreover, drug discovery service companies still need to deal with the problem of a scarcity of trained employees.
| Attributes | Details |
|---|---|
| Drug Discovery Services Market Share (2022) | US$ 17.5 billion |
| Drug Discovery Services Market Share (2023) | US$ 19.7 billion |
| Drug Discovery Services Market Share (2033) | US$ 76.5 billion |
| Drug Discovery Services Market Share (2023 to 2033) | 14.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
In 2022, the global drug discovery services market size stood at US$ 17.5 billion. The market share is expanding rapidly due to the rising market dynamics for pharmaceuticals. Technical developments are likely to amplify market development. An increase in the adoption of novel methodologies for discovery is observed. Escalating demand for generic medications and an increase in patients expiring, all contribute to rising drug distribution.
The increased research and development in the pharmaceutical industry bolster the market’s growth prospects. The evolution of the healthcare industry combined with the rise in demand for generic medications augments the demand for drug discovery services. The rising geriatric population, and technical developments in drug discovery services, all accelerate the market's growth. Additionally, the growing pharmaceutical sector and a surge in contract development services aid market expansion. Growing manufacturing companies that are promoting drug discovery operations boost sales of drug discovery services.
Other factors that positively influence drug discovery trends include:
Pharmaceutical companies occupy lion’s share in the global market. The segment accounted for 42% market share in 2022. Pharmaceutical companies rely on market trends and intelligence to devise drug discovery strategies. They collaborate with research institutions and Contract Research Organizations (CROs) to research specific ailments for target audiences. Therefore, the increasing funding from pharmaceutical companies for new drug discoveries bolsters market growth. Moreover, the development and launch of novel drugs give a boost to market growth.
In terms of market share, the Hit-to-lead identification method is the dominant segment. A hit compound is a molecule that exhibits appropriate activity in a screening assay. Researchers use a slew of methods to find the hit molecule. Although, the conventional technique of high-throughput screening is the standard one. Therefore, the lead optimization segment is expected to see increased demand as technology advances and new state-of-the-art facilities arise.
The medicinal chemistry services segment is predicted to increase at a high-double-digit CAGR throughout the forecast period.
The trend of pharmaceutical companies outsourcing research and development services is growing. The expanding drug discovery and development activities and R&D investments are driving the market forward.
During the projection period, the biological services segment in the drug discovery market is expected to increase at a high CAGR.
Small molecules accounted for a huge portion of the drug discovery services market in 2022. The biologics segment is predicted to expand at a remarkable CAGR in the coming years. The growing use of small-molecule medications to treat chronic diseases surges the demand for these drugs.
Small-molecule pharmaceuticals, even though, dominate the global pharmaceutical market, biologics, biosimilars, and large-molecule drugs are gaining market share. Primarily due to the introduction of new biologic-based treatments and rising earnings from current biologics. In addition, biologics and biosimilars necessitate more specialized testing services than small molecules at each level. Therefore, in the next few years, the growing demand for outsourcing these activities to CROs is likely to fuel the expansion of the market.
Oncology dominated the drug discovery services market in terms of therapeutic areas. It is predicted to continue to do so throughout the forecast period. The segment accounted for an impressive 39.7% market share in 2022. Cancer medicines are in high demand due to increasing cancer cases worldwide. This is likely to make the segment a prominent shareholder in the next years.
Principal Consultant
North America is a global leader in research and development spending in the pharmaceutical industry. The region accounted for a massive 35.2% market share in 2022. The region is also an outsize market for bulk medications and ready-to-use dosage forms.
The United States accounted for 24.1% market share in 2022. The region’s market works as a free economy, with transparent trading practices and anti-competitive actions restricted. Since biologics is more expensive, the United States has a lot of room for biosimilars. As a result, the United States drug discovery services market is one of the primary competitors for biosimilars.
Remicade, Enbrel, Rituximab, Adalimumab, Infliximab, Etanercept, Darbepoetin Alpha, and other drugs are among the popular players in the United States. As a result of the factors mentioned above, the market is expected to grow rapidly over the forecast period. The progressive increase in regional healthcare spending aids new pharmaceutical technology advancements.
The global drug discovery services market is competitive, with Laboratory Corporation of America Holdings (United States), Charles River Laboratories International Inc. (United States), WuXi AppTec (China), and Thermo Fisher Scientific Inc. (United States) collectively accounting for a large portion of the market. The United States-based company, Laboratory Corporation of America Holdings, is a prominent player in the global market.
These key players in the global drug discovery market focus on a broad spectrum of clients. They emphasize incorporating modern and advanced technology-enabled solutions. Increasing investments in joint ventures & partnerships are likely to be prevalent as key strategies. Extensive quality systems and processes contribute to the growth of businesses operating in the market. These companies may use organic and inorganic growth techniques, such as acquisitions and expansions, to tap into new demographics.
Several drugs are pending approval from the United States Food and Drug Administration (FDA).
Anticipated Drug Approvals in 2023:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market attained a revenue of US$ 17.5 billion in 2022.
Increasing funding and reimbursement initiatives increases market demand.
Pharmaceutical companies offer lucrative opportunities.
The hit-to-lead identification method is the dominant segment.
The market is estimated to secure a valuation of US$ 19.7 billion in 2023.
1. Executive Summary | Drug Discovery Services Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Process
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Process, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Process, 2023 to 2033
5.3.1. Target Selection
5.3.2. Target Validation
5.3.3. Hit-to-Lead Identification
5.3.4. Lead Optimization
5.3.5. Candidate Validation
5.4. Y-o-Y Growth Trend Analysis By Process, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Process, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
6.3.1. Chemistry Services
6.3.2. Biology Services
6.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033
7.3.1. Small Molecules Drugs
7.3.2. Biologics Drugs
7.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutic Area
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Therapeutic Area, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutic Area, 2023 to 2033
8.3.1. Neurology
8.3.2. Infectious and Immune System Diseases
8.3.3. Digestive System Diseases
8.3.4. Oncology
8.3.5. Other Therapeutic Area
8.4. Y-o-Y Growth Trend Analysis By Therapeutic Area, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Therapeutic Area, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
9.3.1. Pharmaceutical & Biotechnology Companies
9.3.2. Academic Institutes
9.3.3. Manufacturing
9.3.4. Other End Users
9.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
9.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
10.1. Introduction
10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. South Asia
10.3.5. East Asia
10.3.6. Oceania
10.3.7. MEA
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. The USA
11.2.1.2. Canada
11.2.2. By Process
11.2.3. By Type
11.2.4. By Drug Type
11.2.5. By Therapeutic Area
11.2.6. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Process
11.3.3. By Type
11.3.4. By Drug Type
11.3.5. By Therapeutic Area
11.3.6. By End User
11.4. Key Takeaways
12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Brazil
12.2.1.2. Mexico
12.2.1.3. Rest of Latin America
12.2.2. By Process
12.2.3. By Type
12.2.4. By Drug Type
12.2.5. By Therapeutic Area
12.2.6. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Process
12.3.3. By Type
12.3.4. By Drug Type
12.3.5. By Therapeutic Area
12.3.6. By End User
12.4. Key Takeaways
13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Germany
13.2.1.2. United Kingdom
13.2.1.3. France
13.2.1.4. Spain
13.2.1.5. Italy
13.2.1.6. Rest of Europe
13.2.2. By Process
13.2.3. By Type
13.2.4. By Drug Type
13.2.5. By Therapeutic Area
13.2.6. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Process
13.3.3. By Type
13.3.4. By Drug Type
13.3.5. By Therapeutic Area
13.3.6. By End User
13.4. Key Takeaways
14. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Malaysia
14.2.1.3. Singapore
14.2.1.4. Thailand
14.2.1.5. Rest of South Asia
14.2.2. By Process
14.2.3. By Type
14.2.4. By Drug Type
14.2.5. By Therapeutic Area
14.2.6. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Process
14.3.3. By Type
14.3.4. By Drug Type
14.3.5. By Therapeutic Area
14.3.6. By End User
14.4. Key Takeaways
15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Process
15.2.3. By Type
15.2.4. By Drug Type
15.2.5. By Therapeutic Area
15.2.6. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Process
15.3.3. By Type
15.3.4. By Drug Type
15.3.5. By Therapeutic Area
15.3.6. By End User
15.4. Key Takeaways
16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. Australia
16.2.1.2. New Zealand
16.2.2. By Process
16.2.3. By Type
16.2.4. By Drug Type
16.2.5. By Therapeutic Area
16.2.6. By End User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Process
16.3.3. By Type
16.3.4. By Drug Type
16.3.5. By Therapeutic Area
16.3.6. By End User
16.4. Key Takeaways
17. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
17.2.1. By Country
17.2.1.1. GCC Countries
17.2.1.2. South Africa
17.2.1.3. Israel
17.2.1.4. Rest of MEA
17.2.2. By Process
17.2.3. By Type
17.2.4. By Drug Type
17.2.5. By Therapeutic Area
17.2.6. By End User
17.3. Market Attractiveness Analysis
17.3.1. By Country
17.3.2. By Process
17.3.3. By Type
17.3.4. By Drug Type
17.3.5. By Therapeutic Area
17.3.6. By End User
17.4. Key Takeaways
18. Key Countries Market Analysis
18.1. USA
18.1.1. Pricing Analysis
18.1.2. Market Share Analysis, 2022
18.1.2.1. By Process
18.1.2.2. By Type
18.1.2.3. By Drug Type
18.1.2.4. By Therapeutic Area
18.1.2.5. By End User
18.2. Canada
18.2.1. Pricing Analysis
18.2.2. Market Share Analysis, 2022
18.2.2.1. By Process
18.2.2.2. By Type
18.2.2.3. By Drug Type
18.2.2.4. By Therapeutic Area
18.2.2.5. By End User
18.3. Brazil
18.3.1. Pricing Analysis
18.3.2. Market Share Analysis, 2022
18.3.2.1. By Process
18.3.2.2. By Type
18.3.2.3. By Drug Type
18.3.2.4. By Therapeutic Area
18.3.2.5. By End User
18.4. Mexico
18.4.1. Pricing Analysis
18.4.2. Market Share Analysis, 2022
18.4.2.1. By Process
18.4.2.2. By Type
18.4.2.3. By Drug Type
18.4.2.4. By Therapeutic Area
18.4.2.5. By End User
18.5. Germany
18.5.1. Pricing Analysis
18.5.2. Market Share Analysis, 2022
18.5.2.1. By Process
18.5.2.2. By Type
18.5.2.3. By Drug Type
18.5.2.4. By Therapeutic Area
18.5.2.5. By End User
18.6. United Kingdom
18.6.1. Pricing Analysis
18.6.2. Market Share Analysis, 2022
18.6.2.1. By Process
18.6.2.2. By Type
18.6.2.3. By Drug Type
18.6.2.4. By Therapeutic Area
18.6.2.5. By End User
18.7. France
18.7.1. Pricing Analysis
18.7.2. Market Share Analysis, 2022
18.7.2.1. By Process
18.7.2.2. By Type
18.7.2.3. By Drug Type
18.7.2.4. By Therapeutic Area
18.7.2.5. By End User
18.8. Spain
18.8.1. Pricing Analysis
18.8.2. Market Share Analysis, 2022
18.8.2.1. By Process
18.8.2.2. By Type
18.8.2.3. By Drug Type
18.8.2.4. By Therapeutic Area
18.8.2.5. By End User
18.9. Italy
18.9.1. Pricing Analysis
18.9.2. Market Share Analysis, 2022
18.9.2.1. By Process
18.9.2.2. By Type
18.9.2.3. By Drug Type
18.9.2.4. By Therapeutic Area
18.9.2.5. By End User
18.10. India
18.10.1. Pricing Analysis
18.10.2. Market Share Analysis, 2022
18.10.2.1. By Process
18.10.2.2. By Type
18.10.2.3. By Drug Type
18.10.2.4. By Therapeutic Area
18.10.2.5. By End User
18.11. Malaysia
18.11.1. Pricing Analysis
18.11.2. Market Share Analysis, 2022
18.11.2.1. By Process
18.11.2.2. By Type
18.11.2.3. By Drug Type
18.11.2.4. By Therapeutic Area
18.11.2.5. By End User
18.12. Singapore
18.12.1. Pricing Analysis
18.12.2. Market Share Analysis, 2022
18.12.2.1. By Process
18.12.2.2. By Type
18.12.2.3. By Drug Type
18.12.2.4. By Therapeutic Area
18.12.2.5. By End User
18.13. Thailand
18.13.1. Pricing Analysis
18.13.2. Market Share Analysis, 2022
18.13.2.1. By Process
18.13.2.2. By Type
18.13.2.3. By Drug Type
18.13.2.4. By Therapeutic Area
18.13.2.5. By End User
18.14. China
18.14.1. Pricing Analysis
18.14.2. Market Share Analysis, 2022
18.14.2.1. By Process
18.14.2.2. By Type
18.14.2.3. By Drug Type
18.14.2.4. By Therapeutic Area
18.14.2.5. By End User
18.15. Japan
18.15.1. Pricing Analysis
18.15.2. Market Share Analysis, 2022
18.15.2.1. By Process
18.15.2.2. By Type
18.15.2.3. By Drug Type
18.15.2.4. By Therapeutic Area
18.15.2.5. By End User
18.16. South Korea
18.16.1. Pricing Analysis
18.16.2. Market Share Analysis, 2022
18.16.2.1. By Process
18.16.2.2. By Type
18.16.2.3. By Drug Type
18.16.2.4. By Therapeutic Area
18.16.2.5. By End User
18.17. Australia
18.17.1. Pricing Analysis
18.17.2. Market Share Analysis, 2022
18.17.2.1. By Process
18.17.2.2. By Type
18.17.2.3. By Drug Type
18.17.2.4. By Therapeutic Area
18.17.2.5. By End User
18.18. New Zealand
18.18.1. Pricing Analysis
18.18.2. Market Share Analysis, 2022
18.18.2.1. By Process
18.18.2.2. By Type
18.18.2.3. By Drug Type
18.18.2.4. By Therapeutic Area
18.18.2.5. By End User
18.19. GCC Countries
18.19.1. Pricing Analysis
18.19.2. Market Share Analysis, 2022
18.19.2.1. By Process
18.19.2.2. By Type
18.19.2.3. By Drug Type
18.19.2.4. By Therapeutic Area
18.19.2.5. By End User
18.20. South Africa
18.20.1. Pricing Analysis
18.20.2. Market Share Analysis, 2022
18.20.2.1. By Process
18.20.2.2. By Type
18.20.2.3. By Drug Type
18.20.2.4. By Therapeutic Area
18.20.2.5. By End User
18.21. Israel
18.21.1. Pricing Analysis
18.21.2. Market Share Analysis, 2022
18.21.2.1. By Process
18.21.2.2. By Type
18.21.2.3. By Drug Type
18.21.2.4. By Therapeutic Area
18.21.2.5. By End User
19. Market Structure Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Market Share Analysis of Top Players
19.3.1. By Regional
19.3.2. By Process
19.3.3. By Type
19.3.4. By Drug Type
19.3.5. By Therapeutic Area
19.3.6. By End User
20. Competition Analysis
20.1. Competition Deep Dive
20.1.1. Laboratory Corporation of America Holdings
20.1.1.1. Overview
20.1.1.2. Product Portfolio
20.1.1.3. Profitability by Market Segments
20.1.1.4. Sales Footprint
20.1.1.5. Strategy Overview
20.1.1.5.1. Marketing Strategy
20.1.2. Charles River Laboratories International Inc.
20.1.2.1. Overview
20.1.2.2. Product Portfolio
20.1.2.3. Profitability by Market Segments
20.1.2.4. Sales Footprint
20.1.2.5. Strategy Overview
20.1.2.5.1. Marketing Strategy
20.1.3. Genscript Biotech Corporation
20.1.3.1. Overview
20.1.3.2. Product Portfolio
20.1.3.3. Profitability by Market Segments
20.1.3.4. Sales Footprint
20.1.3.5. Strategy Overview
20.1.3.5.1. Marketing Strategy
20.1.4. Thermo Fisher Scientific Inc.
20.1.4.1. Overview
20.1.4.2. Product Portfolio
20.1.4.3. Profitability by Market Segments
20.1.4.4. Sales Footprint
20.1.4.5. Strategy Overview
20.1.4.5.1. Marketing Strategy
20.1.5. Pharmaron Beijing Co., Ltd.
20.1.5.1. Overview
20.1.5.2. Product Portfolio
20.1.5.3. Profitability by Market Segments
20.1.5.4. Sales Footprint
20.1.5.5. Strategy Overview
20.1.5.5.1. Marketing Strategy
20.1.6. Evotec SE
20.1.6.1. Overview
20.1.6.2. Product Portfolio
20.1.6.3. Profitability by Market Segments
20.1.6.4. Sales Footprint
20.1.6.5. Strategy Overview
20.1.6.5.1. Marketing Strategy
20.1.7. Eurofins Scientific SE
20.1.7.1. Overview
20.1.7.2. Product Portfolio
20.1.7.3. Profitability by Market Segments
20.1.7.4. Sales Footprint
20.1.7.5. Strategy Overview
20.1.7.5.1. Marketing Strategy
20.1.8. Pharmaceutical Product Development, Inc.
20.1.8.1. Overview
20.1.8.2. Product Portfolio
20.1.8.3. Profitability by Market Segments
20.1.8.4. Sales Footprint
20.1.8.5. Strategy Overview
20.1.8.5.1. Marketing Strategy
20.1.9. Piramal Enterprises Limited
20.1.9.1. Overview
20.1.9.2. Product Portfolio
20.1.9.3. Profitability by Market Segments
20.1.9.4. Sales Footprint
20.1.9.5. Strategy Overview
20.1.9.5.1. Marketing Strategy
20.1.10. Syngene International Limited
20.1.10.1. Overview
20.1.10.2. Product Portfolio
20.1.10.3. Profitability by Market Segments
20.1.10.4. Sales Footprint
20.1.10.5. Strategy Overview
20.1.10.5.1. Marketing Strategy
21. Assumptions & Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Drug Discovery Services Market
